Eli Rallo's mom planned her bridal shower and asked guests to bring Rallo either a romance novel or a piece of lingerie as a gift. The author and TikTok star, 27, wore an elegant vintage Ralph Lauren gown to her pre-wedding event.

The drugmaker unveiled a new Zepbound delivery system as its main rival absorbed fresh clinical and stock-market blows. It’s a good day to be the pharmaceutical giant Eli Lilly.

Some analysts are worried that the artificial intelligence (AI) bubble will burst soon, causing a market crash. Whether or not there's something to these fears, it's a good idea for investors to buy shares of companies that can survive downturns and thrive long after.

Feb 12 (Reuters) - Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision by the U.S. Food and Drug Administration in April.

The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or the multi-dose pen that delivers four weekly injections from a single device.

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’s top growth stock picks. On February 18, Eli Lilly and Company (NYSE:LLY) said using Taltz (ixekizumab) together with Zepbound (tirzepatide) worked better than Taltz alone in adults who had moderate-to-severe plaque psoriasis and also had obesity or were overweight.

The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date in a late-stage trial.

Eli Lilly shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 75 to 82.